HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 50, 51793-51803, December 10, 2004

This Article Full Text Full Text (PDF) All Versions of this Article: 279/50/51793    most recent M407382200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meads, M. B. Articles by Medveczky, P. G. Search for Related Content PubMed PubMed Citation Articles by Meads, M. B. Articles by Medveczky, P. G. Social Bookmarking                      What's this?

Kaposi's Sarcoma-associated Herpesvirus-encoded Viral Interleukin-6 Is Secreted and Modified Differently Than Human Interleukin-6

EVIDENCE FOR A UNIQUE AUTOCRINE SIGNALING MECHANISM^*

Mark B. Meads and Peter G. Medveczky

Viral interleukin-6 (vIL-6) is a homolog of cellular IL-6 that is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV) genome. vIL-6 binds to the IL-6 signal transducer gp130 without the cooperation of the IL-6 high affinity receptor to induce STAT3 DNA binding and cell proliferation. Although vIL-6 is believed to be important in the pathogenesis of KSHV-induced diseases, its secretion and post-translational modifications have not previously been characterized. Pulse-chase analysis revealed that the half-time of vIL-6 secretion is 8-fold longer than that of human IL-6. Yet, the vIL-6 signal sequence targets human IL-6 secretion to nearly wild-type levels. Surprisingly, vIL-6 was not secreted from a cell line that does not express gp130 but expression of human gp130 in these cells enabled the secretion of vIL-6. Consistent with this observation, complete maturation of gp130 N-glycans is inhibited by vIL-6 coexpression, suggesting that the binding of the receptor to vIL-6 occurs intracellularly in early or pre-Golgi compartments. Furthermore, a vIL-6 mutant containing an endoplasmic reticulum retention signal is not secreted but does still induce receptor activation and signaling. Secreted vIL-6 is completely glycosylated at both possible N-glycosylaton sites and contains a large proportion of immature high-mannose glycans that is not typical of cytokines. These findings suggest that vIL-6 may induce gp130 signaling by an exclusively autocrine mechanism that relies on intracellular binding to its receptor. During KSHV infection, vIL-6 may only induce signaling in KSHV-infected cells to benefit the viral life cycle and promote oncogenic transformation.

Received for publication, July 1, 2004

^* This work was supported by Grant 1R01CA75894 from the National Institutes of Health (to P. G. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by Training Grant T32DA07245 from the National Institutes of Health.

To whom correspondence should be addressed. Tel.: 813-974-2372; Fax: 813-974-4151; E-mail: pmedvecz{at}hsc.usf.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Chen, Y. B. Choi, G. Sandford, and J. Nicholas Determinants of Secretion and Intracellular Localization of Human Herpesvirus 8 Interleukin-6 J. Virol., July 1, 2009; 83(13): 6874 - 6882. [Abstract] [Full Text] [PDF]

				N. Adam, B. Rabe, J. Suthaus, J. Grotzinger, S. Rose-John, and J. Scheller Unraveling Viral Interleukin-6 Binding to gp130 and Activation of STAT-Signaling Pathways Independently of the Interleukin-6 Receptor J. Virol., May 15, 2009; 83(10): 5117 - 5126. [Abstract] [Full Text] [PDF]

				D. Chen, G. Sandford, and J. Nicholas Intracellular Signaling Mechanisms and Activities of Human Herpesvirus 8 Interleukin-6 J. Virol., January 15, 2009; 83(2): 722 - 733. [Abstract] [Full Text] [PDF]

				P. Gasperini, S. Sakakibara, and G. Tosato Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis J. Leukoc. Biol., October 1, 2008; 84(4): 994 - 1000. [Abstract] [Full Text] [PDF]

				M. de Turenne-Tessier and T. Ooka Post-translational modifications of Epstein Barr virus BARF1 oncogene-encoded polypeptide J. Gen. Virol., October 1, 2007; 88(10): 2656 - 2661. [Abstract] [Full Text] [PDF]

				F.-C. Ye, D. J. Blackbourn, M. Mengel, J.-P. Xie, L.-W. Qian, W. Greene, I-T. Yeh, D. Graham, and S.-J. Gao Kaposi's Sarcoma-Associated Herpesvirus Promotes Angiogenesis by Inducing Angiopoietin-2 Expression via AP-1 and Ets1 J. Virol., April 15, 2007; 81(8): 3980 - 3991. [Abstract] [Full Text] [PDF]

				D. Chen and J. Nicholas Structural Requirements for gp80 Independence of Human Herpesvirus 8 Interleukin-6 (vIL-6) and Evidence for gp80 Stabilization of gp130 Signaling Complexes Induced by vIL-6 J. Virol., October 1, 2006; 80(19): 9811 - 9821. [Abstract] [Full Text] [PDF]

				M. Kovaleva, I. Bussmeyer, B. Rabe, J. Grotzinger, E. Sudarman, J. Eichler, U. Conrad, S. Rose-John, and J. Scheller Abrogation of Viral Interleukin-6 (vIL-6)-Induced Signaling by Intracellular Retention and Neutralization of vIL-6 with an Anti-vIL-6 Single-Chain Antibody Selected by Phage Display. J. Virol., September 1, 2006; 80(17): 8510 - 8520. [Abstract] [Full Text] [PDF]